<![CDATA[Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications]]>

RegulatoryapprovedPembrolizumab (subcutaneous)Berahyaluronidase alfaPositive

AI Analysis

Summary

Subcutaneous pembrolizumab with berahyaluronidase alfa received Japanese regulatory approval for all tumor indications, supported by phase 3 MK-3475A-D77 trial data.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa for all tumor indications

Importance:7/10

Sentiment:

0.80

regulatory approvalJapanoncologysubcutaneous formulationPhase 3

Related Companies

$MRK

Read the original article

Published by Cancer Network on September 23, 2026 3:00 PM

Read Original